Quest Diagnostics (DGX)

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.

This weekend's stocks to watch are defensive plays. They boast strong relative strength, but still suffered losses amid the market sell-off.

8 Upcoming Dividend Increases During Volatile Times

Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.

Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.

DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.